The original Motion Displacement Test (MDT) was first developed in the early 1980s by Professor Fitzke at the Institute of Ophthalmology, London [1, 2]. The original test used a single line stimulus which was presented just above the blind spot (15,9) on a BBC computer (Figure 1).
Figure 1. Diagrammatic representation of original single line MDT
The white circle corresponds to central fixation (0,0) and the open circle the optic nerve head.

The single line MDT was found to be a predictor of glaucomatous field loss,[3] with evidence of elevated motion displacement threshold in areas of the visual field estimated to be normal by standard automated perimetry (SAP).[4] The MDT was also found to be robust to the effect of media opacity.[5, 6] It was these properties that provided the rational to take the test onto a multi-location format in 1999.
Epidemiology studies show us that the global estimate for open angle and angle closure glaucoma in the region of 60 million. This figure is expected to approach 80 million by 2020. At least 50% of glaucoma sufferers in the industrial world are undiagnosed, with this figure reaching 90% in the developing world.[7-17]
The vision of the new Moorfields MDT is to address the global challenge of glaucoma detection by providing a modern, windows-based test suitable for standard PC use. The current test is presented on a 15-inch laptop computer with the aim of offering affordable and portability for case-finding in the community.
The new Moorfields MDT has been under development since 1999 by the Glaucoma Research Unit at Moorfields in collaboration with the Institute of Ophthalmology, UCL. The partnership expanded to include City University, London in 2006. The test development has been strengthened by this university led research and the Moorfields MDT was awarded overall winner of the MRC translational research awards in the Medical Futures competition of 2008.
The new Moorfields MDT is a multi-location test which is presented on a standard computer screen. The patient is asked to look at a central spot and to press the computer mouse each time a line on the screen is seen to move.
The current test uses 32 line stimuli, which are scaled by estimate of retinal ganglion cell density. Each location corresponds to a location on the Humphrey 24-2 program, allowing pointwise comparison between the two instruments. The locations are selected by application of the Garway-Heath map of the anatomic relationship of the optic disc to the visual field.[18] The new 32-location MDT fits on a standard 15-inch laptop screen at a test distance of 30 cm.
The line stimuli are white (124 cd/m2) and presented on a grey background (10 cd/m2), giving a Michelson contrast of 85%. Each stimulus presentation is three oscillations at 200 msec per cycle.[19, 20] The threshold is recorded as the minimum detectable displacement, which is measured in minutes of arc. Motion displacement sensitivity is greater than predicted from retinal ganglion cell spacing and it therefore falls into the category of hyperacuity.[21-23] The MDT task is to discriminate the positional change between two lines and may be regarded as a temporal form of vernier acuity.
Study of the summation properties of the MDT stimulus shows a linear relationship with the stimulus energy ([stimulus area] * [stimulus luminance – background luminance]) giving the relationship T = k √E [T = mdt threshold; K = constant; E = stimulus energy]. This threshold energy displacement law (TED) may be used to predict MDT threshold for different configurations of stimuli. Equivalent thresholds are found for stimuli of equivalent energy, showing that Ricco’s law applies to the MDT stimulus (figure 2).[24]
Figure 2. Plot of log MDT threshold as a function of log stimulus energy

Recent work has included the development of a normative database and pilot comparison with glaucoma. The results of these studies were presented at The Association for Research in Vision and Ophthalmology (ARVO) meeting 2008 (Florida, USA), The International Perimetric Society (IPS) meeting 2008 (Nara, Japan) and the European Glaucoma Society (EGS) meeting 2008 (Berlin, Germany).
City University has developed adaptive algorithms over the last two years which have the benefit of reducing the test duration. The Moorfields MDT now offers two new strategies:
These two new strategies are currently undergoing validation in a collaborative international study which will compare the diagnostic precision of the Moorfields MDT with Standard Automated Perimetry (SAP), the Frequency Doubling Test (FDT) and the new Heidelberg Edge Perimeter (HEP) in very early ‘glaucoma’ (glaucoma selection criterion is by ‘structure’ using the Heidelberg retinal tomograph (HRT): abnormal Moorfields regression, rim area greater than 0.5 mm2 and a disc area within the normal range).
The study collaborators are:
Comparison of the Moorfields MDT with Octopus and Pulsar perimetry www.octopus.ch is being undertaken by the Hôpital Ophtalmique Jules-Gonin, University of Lausanne, Switzerland. This project is led by Dr Eamon Sharkawi with Dr Corinne Schnyder and Dr Hana Abouzeid. The study uses the same selection criterion as above.
The ESTA detection program was reported to outperform the Humphrey 76 point screening test, the Frequency Doubling Matrix screening test and Heidelberg Retinal Tomography in the preliminary findings of the St Kitts Eye Study presented by Associate Professor Paul Artes at ARVO 2008 (The St Kitts Eye Study (SKES): Design and Initial Findings. Artes et al. IOVS 2008; 49: ARVO E-abstract 4080; http://www.scribd.com/doc/14946158/ArtesARVO09-StKitts ).
The ESTA program is also taking part in a community study which is led by Alfonso Antón MD PhD and Monica Fallon at the Hospital de la Esperanza y el Mar, Instituto Municipal de Investigaciones Médicas (IMIM, IMAS) and the Universidad Autónoma de Barcelona. The study objective is to assess the cost/effectiveness of screening for glaucoma through telemedicine.
The ESTA program will shortly be joining studies at the Singapore National Eye Centre (SNEC) http://www.snec.com.sg/clinical/staff_glaucoma.asp led by Assoc Prof Tin Aung and Dr Alicia How.
A study will take place in 5 GP practices in Northern Greece led by Professor Fotis Topouzis and Dr Androniki Glystra at the Aristotle and University of Thessaloniki (AUTH), Greece.
A community pilot study is planned with Dr Paul Healey and Ankur Mehta in Sydney Australia.
MHRA approval was granted to the Moorfields MDT in 2006 (CE / 2006 / 009073).
Register here for notification when the Moorfields MDT is officially released.
The commercialisation of the Moorfields MDT is being led by UCLB http://www.uclb.com/ It is anticipated it will be available in 2011 on completion of the validation programs.